CN114703169A - L-threonine aldolase mutant R318L/H128N and application thereof - Google Patents
L-threonine aldolase mutant R318L/H128N and application thereof Download PDFInfo
- Publication number
- CN114703169A CN114703169A CN202210466832.7A CN202210466832A CN114703169A CN 114703169 A CN114703169 A CN 114703169A CN 202210466832 A CN202210466832 A CN 202210466832A CN 114703169 A CN114703169 A CN 114703169A
- Authority
- CN
- China
- Prior art keywords
- mutant
- threonine aldolase
- amino acid
- gene
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108030001992 L-threonine aldolases Proteins 0.000 title claims abstract description 76
- 150000001413 amino acids Chemical group 0.000 claims abstract description 22
- 229960001104 droxidopa Drugs 0.000 claims abstract description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 20
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004471 Glycine Substances 0.000 claims abstract description 10
- 229940024606 amino acid Drugs 0.000 claims abstract description 10
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 3,4-Dihydroxy hydroxymethyl benzene Natural products OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 5
- QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 9
- 238000006555 catalytic reaction Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 6
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 6
- 229960001327 pyridoxal phosphate Drugs 0.000 claims description 5
- 238000005882 aldol condensation reaction Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 102000002667 Glycine hydroxymethyltransferase Human genes 0.000 abstract description 9
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 9
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- CXIYBDIJKQJUMN-QMMMGPOBSA-N (2s)-2-anilino-3-hydroxypropanoic acid Chemical compound OC[C@@H](C(O)=O)NC1=CC=CC=C1 CXIYBDIJKQJUMN-QMMMGPOBSA-N 0.000 abstract 1
- QXWYKJLNLSIPIN-JGVFFNPUSA-N droxidopa Chemical compound OC(=O)[C@@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-JGVFFNPUSA-N 0.000 description 37
- 102000004190 Enzymes Human genes 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 21
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2s,3s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical class [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000001976 enzyme digestion Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 208000001089 Multiple system atrophy Diseases 0.000 description 4
- 241000282453 Ursus americanus Species 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- REFMEZARFCPESH-UHFFFAOYSA-M sodium;heptane-1-sulfonate Chemical compound [Na+].CCCCCCCS([O-])(=O)=O REFMEZARFCPESH-UHFFFAOYSA-M 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- 108010021466 Mutant Proteins Proteins 0.000 description 3
- 206010031127 Orthostatic hypotension Diseases 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical group O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 206010013578 Dizziness postural Diseases 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700011066 PreScission Protease Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- -1 L-threo- (3 Chemical compound 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- PTKSEFOSCHHMPD-UHFFFAOYSA-N midodrine Chemical compound COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-UHFFFAOYSA-N 0.000 description 1
- 229960001094 midodrine Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000006918 subunit interaction Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/02—Aldehyde-lyases (4.1.2)
- C12Y401/02005—L-Threonine aldolase (4.1.2.5)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to threonine aldolase, and in particular relates to an L-threonine aldolase mutant R318L/H128N and application thereof. The amino acid sequence of the L-threonine aldolase mutant is shown as SEQ ID NO. 3, and is obtained by changing Arg to Leu at amino acid 318 and changing His to Asn at amino acid 128 of the L-threonine aldolase with the amino acid sequence of SEQ ID NO. 1. The mutant has 92.89% diastereoselectivity in the reaction for catalyzing the synthesis of droxidopa [ L-threo- (3, 4-dihydroxy) phenylserine ] by 3, 4-dihydroxybenzaldehyde and glycine, the yield reaches 1.26mg/mL, and when the mutant is catalyzed by using a whole cell expressing R318L/H128N, the diastereoselectivity for synthesizing the droxidopa is 94.5%, and the yield is 1.6 mg/mL. The whole cells have great application potential in the biosynthesis of droxidopa.
Description
Technical Field
The invention relates to threonine aldolase, in particular to an L-threonine aldolase mutant R318L/H128N and application thereof.
Background
Droxidopa (L-threo-DOPS, i.e. L-threo- (3, 4-dihydroxy) phenylserine) is the only drug used to treat parkinson-related Neurogenic Orthostatic Hypotension (NOH) since the approval of midodrin in 1996, for the improvement of gait rigidity and orthostatic dizziness caused by parkinson's disease; ameliorating orthostatic hypotension, orthostatic dizziness and fainting caused by Shy-Drager syndrome or familial amyloid neuropathy; improve dizziness and hypodynamia of hemodialysis patients caused by orthostatic hypotension.
At present, the synthetic method of the troxidopa comprises chemical synthesis and enzyme catalysis, and the industrial production of the troxidopa depends on the chemical synthesis. The chemical synthesis method mainly obtains chiral droxidopa through addition reaction, esterification reaction and optical resolution, although the operation is simple, a large amount of water, heavy metals and virulent hydrogen sulfide are used in the reaction process, and the optical resolution causes half of raw material waste, high production cost and potential environmental pollution, and does not meet the atomic economy and environmental protection policies advocated and promoted by the current and future countries. The enzyme catalysis method has the advantages of mild condition, less water consumption (only one tenth of that of the chemical method), no heavy metal pollution, no use of highly toxic chemicals, high chiral selection and the like, and has good application prospect.
Threonine aldolase has very wide application potential, and can catalyze and synthesize chiral pharmaceutical key intermediate beta-hydroxy-alpha-amino acid. Threonine aldolase can be classified into two types, L-type and D-type, according to its stereospecificity at the alpha carbon of threonine as a substrate. The patent application with the title of 'threonine aldolase, coding gene and application in droxidopa biosynthesis' with the application number of 2019109657806 discloses an L-threonine aldolase gene separated from a black bear stool sample, with the total length of 1032bp, coding for an L-threonine aldolase consisting of 343 amino acids. The diastereoselectivity of the enzyme for synthesizing droxidopa by using benzaldehyde and glycine substituted by hydroxyl at 3-/4-position as substrates is 30%. The low diastereoselectivity greatly hinders the use of this enzyme in the synthesis of troxidopa. Therefore, it is very necessary to develop threonine aldolase with high selectivity for the synthesis of droxidopa.
Disclosure of Invention
Has important influence on the stereoselectivity and the catalytic activity of threonine aldolase
In order to develop threonine aldolase with high selectivity, the invention compares the dissimilarity of wild-type L-threonine aldolase (amino acid sequence is shown as SEQ ID NO: 1) separated from a black bear feces sample and homologous enzyme protein from a primary structure to a high-level structure in a multi-layer system, under the premise that the site influencing the optical property of the wild-type L-threonine aldolase is determined to be arginine at the 318 th site in the former period and arginine (Arg) at the site is changed into leucine (Leu), amino acid His128 with subunit interaction is discovered through semi-rational design and rational design, and the amino acid His at the 128 th site is changed into Asn, so as to obtain an enzyme mutant which is named as L-TA R318L/H128N mutant. The encoding gene (SEQ ID NO:4) of the L-TA R318L/H128N mutant is obtained by utilizing a molecular cloning technology, and the L-TA R318L/H128N mutant enzyme protein is obtained by constructing a GST fusion expression vector of the mutant gene and introducing the GST fusion expression vector into genetically engineered bacterium E.coli BL21 for induction expression. The L-TA R318L/H128N mutant is used as a catalyst, 3-/4-hydroxyl substituted benzaldehyde is used as a substrate, glycine is used as an auxiliary substrate, and 5-pyridoxal phosphate is used as a coenzyme, and an enzyme catalytic reaction is carried out in a proper condition and medium, so that the result shows that the diastereoselectivity of the mutant for synthesizing droxidopa (L-threo-DOPS) is as high as 92.89 percent, which is 3.09 times of that of a wild type, the yield reaches 1.26mg/mL, and the mutant has great application value in the industrial production of droxidopa.
The invention provides an L-threonine aldolase mutant which is characterized in that the amino acid sequence is shown as SEQ ID NO. 3, and the mutant is obtained by changing Arg to Leu at the 318 th amino acid position and changing His to Asn at the 128 th amino acid position of the L-threonine aldolase with the amino acid sequence of SEQ ID NO. 1.
The genes encoding the L-threonine aldolase mutants also belong to the scope of the present invention.
In some preferred embodiments of the invention, the nucleotide sequence of the gene is shown in SEQ ID NO. 4.
Expression cassettes, vectors or recombinant bacteria comprising said genes also belong to the scope of protection of the present invention.
The vector provided by the invention can be a cloning vector, and comprises an L-TA R318L/H128N mutant gene and other elements required by plasmid replication; it may also be an expression vector comprising the L-TA R318L/H128N mutant gene and other elements enabling successful expression of the protein. In some embodiments of the invention, the expression vector is a pGEX-6p-2 vector into which the L-TA R318L/H128N mutant gene is inserted, and the pGEX-6p-2 vector is a known commercially available vector.
The recombinant bacteria provided by the invention can be recombinant bacteria containing a cloning vector, such as E.coli DH5 alpha, and L-TA R318L/H128N mutant genes are replicated by culturing the recombinant bacteria; or a recombinant bacterium containing an expression vector, such as e.coli BL21, cultured under appropriate conditions and expressed as a protein, such as: adding a proper amount of IPTG into the recombinant bacterium culture solution, and inducing the expression of the L-TA R318L/H128N mutant protein at 16 ℃.
The invention also provides a preparation method of the L-threonine aldolase mutant, which comprises the following steps: synthesizing the coding gene of the L-threonine aldolase mutant, constructing an expression vector, transforming protein expression host bacteria, inducing protein expression and purifying.
In a preferred embodiment of the production method of the present invention, the nucleotide sequence of the gene encoding the L-threonine aldolase mutant is shown in SEQ ID NO. 4.
In some embodiments of the preparation method of the present invention, the expression vector is pGEX-6p-2 vector and the protein expression host bacterium is E.coli BL21(DE 3).
The invention also provides a catalyst, the effective component of which comprises the L-threonine aldolase mutant. The catalyst can be used alone or together with other suitable catalysts to improve the diastereoselectivity of the enzyme or to carry out two catalytic reactions one after the other in the same reaction system.
The use of the L-threonine aldolase mutant or the catalyst in aldol condensation reactions also belongs to the scope of protection of the present invention.
In some preferred embodiments of the present invention, droxidopa is synthesized by using the L-threonine aldolase mutant or the catalyst and performing a catalytic reaction using 3, 4-dihydroxybenzaldehyde as a substrate, glycine as a co-substrate, and pyridoxal-5-phosphate as a coenzyme.
In some preferred embodiments of the invention, the catalytic reaction is carried out at a temperature of 15 to 37 ℃ and a pH of 6.0 to 11.0.
The L-TA R318L/H128N mutant can catalyze the aldol condensation reversible reaction of 3, 4-dihydroxy benzaldehyde and glycine under the reaction conditions of 15-37 ℃ and pH 6.0-11.0.
Drawings
FIG. 1 is a schematic diagram of the catalytic synthesis of droxidopa by L-threonine aldolase (L-TA).
FIG. 2 is an SDS-PAGE electrophoresis of L-threonine aldolase mutant R318L/H128N; wherein M is a protein molecular weight standard (Marker); R318L/H128N is a mutant protein, and the molecular weight of the mutant protein is about 38.7 KD.
FIG. 3 HPLC profile of the catalytic product of L-threonine aldolase mutant R318L/H128N; wherein the uppermost spectrum (labeled as R318L/H128N) shows the catalytic product of the L-TAR318L/H128N mutant, and the catalytic reaction is carried out at 25 ℃ and pH 7.4 by using 3, 4-dihydroxybenzaldehyde as a substrate, glycine as an auxiliary substrate and pyridoxal 5-phosphate as a coenzyme; the intermediate spectrum (labeled L-threo-DOPS) is the L-threo-DOPS standard; the lowest spectra (labeled L-DOPS) are the L-threo-DOPS and L-erythro-DOPS racemate standards. The retention time of L-erythro-DOPS was 5.5min, and the retention time of L-threo-DOPS was 6.2 min.
Detailed Description
The invention is further described below in connection with specific examples, which are to be construed as merely illustrative and explanatory and not limiting the scope of the invention in any way.
Main reagents and consumables:
prime STAR Max Premix (2 ×) (cat No. R045A), BamH I restriction enzyme (cat No. 1010S), Xho I restriction enzyme (cat No. 1094S), T4 DNA Ligase (cat No. D2011A), and 10 × T4 Ligase buffer, all purchased from baoz biotechnology limited (da lian);
pGEX-6P-2 plasmid is known Escherichia coli expression vector, which is named as pGEX6P2 and pGEX6P2, the size of the vector is 4985bp, a Tac promoter, a vector label N-GST and vector resistance Ampicillin (Ampicillin), and is purchased from Shanghai Biotechnology limited company, and the laboratory also has storage;
trans5 α competent cells (cat # CD201-01) and E.coli BL21(DE3) competent cells (cat # CD601), both purchased from holo-gold biotechnology, Inc.;
glutaminone Sepharose 4B, purchased from GE Healthcare, cat # 10223836;
PreScission Protease, available from Gen Script Inc., cat No. Z02799-100;
bradford protein concentration assay kit, purchased from Beyotime corporation, cat # P0006;
L-threo-DOPS standard (CAS: 23651-95-8, product number: D4235, molecular formula: C)9H11NO5) LDOPS (L-threo-DOPS and L-erythro-DOPS racemate) standards (CAS: 23651-95-8, product number: d9446) 1-Heptanesulfonic acid sodium salt (CAS: 22767-50-6, molecular formula: c7H15NaO3S), 1, 4-dioxane (CAS: 123-91-1, formula: c4H8O2) Are all purchased from carbofuran technologies, inc;
glycine (CAS: 56-40-6, molecular formula: C)2H5NO2No. a502065), 3, 4-dihydroxybenzaldehyde (CAS: 139-85-5, linear formula: (HO)2C6H3CHO, cat # a601406), pyridoxal 5-phosphate (english name PLP, CAS: 41468-25-1, formula C8H12NO7P, cat # a610455), all purchased from bio-engineering (shanghai) incorporated.
LB Medium
Each 100mL of LB medium contained: 1g tryptone, 0.5g yeast extract, 1g sodium chloride, pH 7.4.
The preparation method comprises the following steps: at 950mL ddH2O10 g tryptone, 5g yeast extract, 10g sodium chloride, then adjusted to pH 7.4 with NaOH, and ddH2And O is metered to 1L. If a solid medium is prepared, 15g of agar per liter are added. Sterilizing with high pressure steam at 121 deg.C for 20 min.
PBS buffer
preparation method of pH 7.4, 10mM PBS: weighing 8g NaCl, 0.2g KCl and 1.44g Na2HPO4And 0.24g KH2PO4Dissolving the mixture in 800mL of distilled water, adjusting the pH value of the solution to 7.4 by using HCl, and finally adding distilled water to a constant volume of 1L. Sterilizing with steam at 121 deg.C for at least 20min, and storing in refrigerator at room temperature or 4 deg.C.
Unless otherwise specified, the reagents used in the following examples are conventional in the art, and are either commercially available or formulated according to methods conventional in the art, and may be of laboratory grade. Unless otherwise specified, the methods used in the following examples are all conventional in the art, and the experimental conditions used are all conventional in the art, and reference may be made to the relevant experimental manuals or manufacturer's instructions.
Example 1 preparation of L-threonine Aldolase R318L/H128N mutant
Design of I, L-threonine aldolase mutant
The wild L-threonine aldolase gene (L-TA gene, SEQ ID NO:2) is isolated from feces samples of healthy black bears in Sichuan black bear protection and incubation bases in the laboratory, the total length of an open reading frame of the L-TA gene is 1032bp, and the encoded L-threonine aldolase consists of 343 amino acids. The isolation and cloning of this gene is described in the text of the patent application with application No. 2019109657806, publication No. CN110592058A, entitled "threonine aldolase, its encoding gene and use in droxidopa biosynthesis", which is incorporated herein by reference in its entirety.
The amino acid sequence (343aa) of the wild-type L-threonine aldolase is:
MYSFKNDYSEGAHPRILETLLRTNLEQCEGYGKDTYCEEAENLIKNKLNNESIEVHFISGGTQTNLIAISAFLRPHEGVISADTGHIFVNEAGSIEATGHKVISVDVVDGKLRRDDILSVLSKFTNEHVVKPKLVYISNSTEIGTIYKKSELEELSKVCRENNLLLFMDGARLGSALSCKENDLTLEDISKLTDAFYIGGTKNGALLGEALVICNKDLQEDFRYHLKQKGAMLAKGRLLGIQFIELFKDDLFFEIGKHENDMADILRDGISRLGYEFLVDSPSNQIFPVFNNDIIRELEKNYGFNIWEKVNEEKTAIRLVTSFATKEEPCLEFIKFLSGLTNK(SEQIDNO:1)
the nucleotide sequence (1032bp) of the coding gene of the wild-type L-threonine aldolase is as follows:
ATGTATAGTTTTAAAAATGATTATAGTGAAGGGGCACATCCTAGAATTCTTGAAACGTTGCTGAGAACAAATTTAGAACAATGTGAAGGTTACGGAAAAGATACATACTGTGAGGAAGCTGAAAACTTAATAAAAAATAAACTAAATAATGAGTCTATTGAAGTCCATTTCATATCTGGAGGTACACAAACTAACTTAATAGCAATATCTGCATTTTTAAGGCCTCATGAGGGTGTTATATCAGCAGATACAGGGCATATATTTGTAAATGAAGCAGGTTCAATAGAAGCAACAGGACATAAGGTGATATCTGTTGATGTTGTGGATGGTAAACTAAGAAGAGACGATATACTATCAGTATTGAGTAAGTTTACTAATGAGCATGTTGTAAAACCAAAGCTTGTTTATATATCTAACTCTACTGAAATTGGAACTATATATAAAAAATCTGAATTAGAAGAGTTAAGCAAAGTTTGTAGAGAAAATAATTTATTACTATTTATGGATGGAGCAAGATTAGGATCTGCACTTTCTTGCAAAGAAAATGATTTGACATTAGAAGATATAAGTAAATTAACTGATGCTTTTTATATCGGGGGAACTAAGAATGGAGCTCTTTTAGGAGAAGCACTTGTTATATGTAATAAAGATTTACAGGAAGATTTTAGATATCACTTAAAACAAAAAGGAGCGATGCTTGCTAAGGGAAGGTTGCTTGGAATACAGTTTATAGAATTATTTAAAGATGATTTATTTTTTGAAATAGGAAAACATGAAAATGATATGGCTGATATATTAAGGGATGGAATAAGTAGGCTTGGATATGAATTTTTAGTAGACTCTCCATCTAATCAAATATTCCCAGTATTTAACAATGATATTATAAGAGAATTAGAGAAAAACTATGGATTTAATATATGGGAAAAAGTAAATGAAGAGAAAACTGCAATAAGATTAGTAACATCTTTTGCAACAAAAGAAGAACCTTGTCTAGAGTTTATAAAGTTTTTAAGTGGATTAACTAATAAATAA(SEQIDNO:2)
by comparing the homology of the wild-type L-threonine aldolase and the homologous enzyme protein from the primary structure to the high-level structure in a multi-layer system from multi-angle, the sites influencing the enzymatic properties are determined to be the 318 th amino acid and the 128 th amino acid of the wild-type L-threonine aldolase, and the corresponding nucleotide sequences are the 952-. The codon 952-954 of the wild-type L-TA gene sequence was changed from AGA to CTG and the codon 382-384 was changed from GCT to AAT, so that the 318 th position of the amino acid sequence was changed from the original arginine (R) to leucine (L) and the original histidine (H) to asparagine (N), to obtain an enzyme mutant, named L-TA R318L/H128N mutant, whose amino acid sequence is shown in SEQ ID NO:3 and whose nucleotide sequence of the encoding gene is shown in SEQ ID NO: 4.
II, obtaining L-TA R318L/H128N mutant gene
The L-TA R318L/H128N mutant gene can be obtained by a whole gene synthesis method or a molecular cloning method. The mutant gene was obtained by PCR.
1. Primer design
The obtained L-TA R318L/H128N mutant gene sequence (SEQ ID NO:4) was primed by adding BamH I (GGATCC) at the 5 'end and Xho I (CTCGAG) at the 3' end. The nucleotide sequences of the primers are as follows:
the upstream primer L-TA-R318L-BamH I-F:
5′-CGCGGATCCATGTATAGTTTTAAAAATGATTAT-3′(SEQ ID NO:5),
downstream primer L-TA-R318L-Xho I-R:
5′-CCGCTCGAGTTATTTATTAGTTAATCCACTTA-3′(SEQ ID NO:6)。
the upstream primer L-TA-R318L/H128N-F:
5′-TAAGTTTACTAATGAGAATGTTGTAAAACCAAAGCTTG-3′(SEQ ID NO:7)
the downstream primer L-TA-R318L/H128N-R:
5′-CAAGCTTTGGTTTTACAACATTCTCATTAGTAAACTTAC-3′(SEQ ID NO:8)
the above primers were synthesized by the firm of Venezuelan Biotechnology engineering (Shanghai) Ltd.
2. L-TA R318L/H128N mutant gene clone
The invention is named as follows under the application number of 202010323801.7: the plasmid of the L-TA mutant R318L gene reported in the section "L-threonine aldolase mutant R3318L and its application" was used as a template, and the upstream primer and the downstream primer obtained in step 1 were used to amplify the L-TA R318L/H128N mutant gene according to the following PCR system and procedure.
And (3) PCR system: prime STAR Max Premix (2X) 25. mu.L, plasmid template 0.5. mu.L, upstream primer L-TA R318L/H128N-BamH I-F (10. mu.M) 2. mu.L, downstream primer L-TA-R318L/H128N-Xho I-R (10. mu.M) 2. mu.L, complement ddH2O to a total volume of 50. mu.L.
The PCR procedure was as follows:
a.94 ℃ for 5 min;
b.98 ℃ denaturation 10sec, 47 ℃ annealing 10sec, 72 ℃ extension 10 sec; 40 cycles;
c.72 ℃ extension for 10 min.
The PCR amplification product was detected by 1.2% agarose gel electrophoresis to obtain a band of about 1000bp in size. The band of interest was excised under an ultraviolet lamp, and the L-TA R318L/H128N mutant gene fragment was recovered using the Omega Gel Extraction Kit D2500 according to the Kit instructions.
3. Expression vector construction
(1) Cleavage and ligation
The L-TA R318L/H128N mutant gene and the pGEX-6p-2 vector are subjected to double enzyme digestion by using BamH I and Xho I restriction enzymes respectively. Enzyme cleavage System (Gene): 35 μ L of L-TA R318L/H128N mutant gene, 3 μ L of BamH I enzyme, 3 μ L of Xho I enzyme, and 10 XK buffer6 μ L, and sterile double distilled water is supplemented until the system is 60 μ L. Enzyme digestion system (vector): 2 mu L of pGEX-6p-2 vector, 0.5 mu L of BamH I enzyme, 0.5 mu L of Xho I enzyme, 1 mu L of 10 xK buffer, and sterile double distilled water is supplemented until the system is 10 mu L. The enzyme digestion conditions are as follows: the enzyme was cleaved at 37 ℃ for 3 h.
The cleaved L-TA R318L/H128N mutant gene was then ligated with pGEX-6p-2 linear vector using T4 DNA ligase: 6 mu L of the L-TA R318L/H128N mutant gene after enzyme digestion, 2 mu L of pGEX-6p-2 linear vector, 1 mu L of T4 DNA Ligase and 1 mu L of 10 XT 4 Ligase buffer. Ligation was carried out overnight at 16 ℃ to give the ligation product pGEX-6p-2/L-TA R318L/H128N.
(2) Transformation of
Trans5 alpha competent cells (gold, CD201-01) were placed on ice, 10. mu.L of pGEX-6p-2/L-TA R318L/H128N were added after the cells had thawed, and placed on ice for 30 min. The mixture was heat-shocked at 42 ℃ for 90 seconds and then kept on ice for 2 min. Adding 600 μ L sterile LB liquid medium, shaking at 37 deg.C and 150rpm for 45 min. 200. mu.L of the cultured bacterial suspension was aspirated, spread on Amp + resistant (100. mu.g/mL) LB plate medium, and cultured overnight at 37 ℃ in an inverted manner.
(3) Positive clone screening
A single colony on an LB plate is picked up and inoculated in an Amp + resistant (100 mu g/mL) LB liquid medium, shake-cultured at 37 ℃ and 220rpm until OD 600 is approximately equal to 1.0, and centrifuged at 8000rpm for 5min to collect thalli for plasmid extraction. The Plasmid was extracted using OMEGA Plasmid Mini Kit I (cat # D6943) according to the instructions and identified by double digestion.
Enzyme digestion system:
enzyme cutting conditions are as follows: the enzyme was cleaved at 37 ℃ for 3 h. The products of the restriction enzyme digestion are detected by using 1.2 percent agarose gel electrophoresis, the recombinant plasmid with correct restriction enzyme digestion identification is selected and sent to TAKARA company for sequencing, and the recombinant plasmid with correct sequencing result is used as an expression vector of the L-TA R318L/H128N mutant.
4. GST fusion heterologous expression of enzyme proteins
(1) Coli BL21(DE3) cells transformed with the plasmid
Coli BL21(DE3) competent cells were removed from-80 ℃ and placed on ice. After the cells are thawed, 10. mu.L of expression vector pGEX-6p-2/L-TA R318L/H128N with correct sequencing result is added, and the mixture is placed on ice for 30 min. The mixture was heat-shocked at 42 ℃ for 90 seconds and then kept on ice for 2 min. Adding 600 μ L sterile LB liquid medium, shaking at 37 deg.C and 150rpm for 45 min. 200. mu.L of the cultured bacterial suspension was aspirated, spread on Amp + resistant (100. mu.g/mL) LB plate medium, and cultured overnight at 37 ℃ in an inverted manner. And (3) picking a single colony on the LB plate, carrying out colony PCR identification according to the PCR system and the program in the step 2, and taking the colony with the correct identification result as a protein expression strain.
(2) Protein expression and purification
a. The protein expression strain was inoculated into a sterile LB liquid medium to a final concentration of 100. mu.g/mL ampicillin, and cultured at 37 ℃ and 170 rpm.
b. When OD 600. apprxeq.0.8, IPTG was added to a final concentration of 0.2mM and induced overnight (12h) at 16 ℃ and 180 rpm. The cells were collected by centrifugation at 8000rpm for 5 min.
c. The cells were resuspended in a 1L culture system in 30mL of lysis buffer (pH 7.4, 10mM PBS), and the cell walls were disrupted by an ultra-high pressure nano homogenizer at 4 ℃. The crushed bacteria liquid is evenly distributed into a50 mL sterile centrifuge tube precooled at 4 ℃, centrifuged at 12000rpm for 20min at 4 ℃, and after centrifugation is finished, the supernatant is transferred into the 50mL sterile centrifuge tube precooled at 4 ℃ by a precision pipette gun.
d. Glutathione Sepharose 4B packing (GE Healthcare) was packed into a chromatography column (GE Healthcare) using 5mL of packing per liter of culture system. The absolute ethanol was removed by washing 3 column volumes with 4 ℃ pre-chilled pH 7.4, 10mM sterile PBS. The supernatant from step c was combined with glutaminone Sepharose 4B and suspended vertically for 3h at 4 ℃.
e. After the binding is completed, the filler is precipitated by centrifugation at 500rpm for 5 min. The packing was washed 3-5 column volumes with 4 ℃ pre-chilled pH 7.4, 10mM sterile PBS to remove contaminating proteins.
f. The mixture was digested overnight at 4 ℃ with addition of a 4 ℃ precooled digestion buffer (pH 7.4, 10mM PBS) and PreScission Protease (GenScript, Z02799-100).
g. After the enzyme digestion is finished, discharging the supernatant from the chromatographic column to obtain the L-TAR318L/H128N enzyme solution.
h. The molecular weight of the L-TA R318L/H128N enzyme solution is identified by SDS-PAGE. The concentration of L-TA R318L/H128N enzyme solution was determined using the Bradford protein concentration assay kit (Beyotime, P0006) according to the kit instructions.
The results are shown in FIG. 2, and the SDS-PAGE result shows that the L-TA R318L/H128N mutant is successfully expressed in a soluble way, the molecular weight of the protein is about 38.7KD, and the purity of the enzyme protein is high and is a single band. The concentration of the L-TA R318L/H128N enzyme solution was determined to be 2 mg/mL.
Example 2 Synthesis of droxidopa by L-TAR318L/H128N mutant and detection of the de value
1. Synthesis of droxidopa
After adding 1M glycine, 60mM 3, 4-dihydroxybenzaldehyde and 50. mu.M PLP, 2.8mg of purified L-TA to PBS buffer (pH 7.0), and reacting at 37 ℃ for 4 hours, the sample was ultrafiltered with an ultrafiltration tube (10kDa) to remove insoluble matter. The ultrafiltered sample was lyophilized in a lyophilizer, and then an organic phase solution (90% 0.1% w/v sodium heptanesulfonate/0.1% w/v 1, 4-dioxane) was added to bring to the appropriate concentration.
2. Detection and de value calculation of droxidopa
And (3) diluting the sample obtained after ultrafiltration in the step (1) by 10 times to achieve better HPLC separation effect. The amount of droxidopa (L-threo-DOPS) and its diastereomer (L-erythro-DOPS) in the sample was measured by HPLC. HPLC instrument model number: agilent 1260. Setting parameters: a chromatographic column: COSMOSIL5C18-MS 4.6X 150 mm; the wavelength is 280nm, and the column temperature is 30 ℃; mobile phase: 90% 0.1% (w/v, g/mL) 1-heptanesulfonic acid sodium salt/0.1% (w/v, g/mL)1, 4-dioxane (solvent is distilled water), 10% methanol; the sample volume was 10. mu.L, and the flow rate was 1 mL/min. L-threo-DOPS standards (0.1mg/mL, pH 7.4, 10mM PBS), and racemic standards of L-threo-DOPS and L-erythro-DOPS (0.01mg/mL, pH 7.4, 10mM PBS), respectively, were tested according to the same HPLC parameters.
Determining the amounts of L-threo-DOPS and L-erythro-DOPS in the sample based on the peak areas. The de value (percent diastereomeric excess) is then determined based on the following equation:
[ (amount of L-threo-DOPS-amount of L-erythro-DOPS)/(amount of L-threo-DOPS + amount of L-erythro-DOPS) ]. times.100%.
The HPLC results are shown in FIG. 3, in which the uppermost spectrum (labeled R318L/H128N) is the catalytic product of the L-TAR318L/H128N mutant; the intermediate spectrum (labeled L-threo-DOPS) is the L-threo-DOPS standard; the lowest spectrum (labeled L-DOPS) is the standard for L-threo-DOPS and L-erythro-DOPS racemates. The retention time of L-erythro-DOPS was 5.5min, and the retention time of L-erythro-DOPS was 6.2 min. The L-TAR318L/H128N mutant was calculated to have a diastereoselectivity (de value) of 84.9% in catalyzing the synthesis of droxidopa (L-threo-DOPS) from 3, 4-dihydroxybenzaldehyde and glycine.
Claims (10)
1. An L-threonine aldolase mutant characterized in that the amino acid sequence is shown as SEQ ID NO. 3, and the mutant is obtained by changing Arg to Leu at amino acid 318 and changing His to Asn at amino acid 128 of the L-threonine aldolase with the amino acid sequence of SEQ ID NO. 1.
2. A gene encoding the L-threonine aldolase mutant as described in claim 1.
3. The gene of claim 2, wherein the nucleotide sequence is represented by SEQ ID NO. 4.
4. An expression cassette, vector or recombinant bacterium comprising the gene of claim 2.
5. The method for producing an L-threonine aldolase mutant according to claim 1, comprising the steps of: synthesizing the coding gene of the L-threonine aldolase mutant, constructing an expression vector, transforming protein expression host bacteria, inducing protein expression and purifying.
6. The method of claim 5, wherein: the nucleotide sequence of the coding gene of the L-threonine aldolase mutant is shown as SEQ ID NO. 4.
7. A catalyst comprising the L-threonine aldolase mutant according to claim 1 as an active ingredient.
8. Use of the L-threonine aldolase mutant as defined in claim 1 or the catalyst as defined in claim 7 in an aldol condensation reaction.
9. The use according to claim 8, wherein droxidopa is synthesized by a catalytic reaction using the L-threonine aldolase mutant according to claim 1 or the catalyst according to claim 7, with 3, 4-dihydroxybenzaldehyde as a substrate, glycine as a co-substrate, and pyridoxal-5-phosphate as a co-enzyme.
10. Use according to claim 9, wherein the catalytic reaction is carried out at a temperature of 15-37 ℃ and a pH of 6.0-11.0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210466832.7A CN114703169B (en) | 2022-04-29 | 2022-04-29 | L-threonine aldolase mutant R318L/H128N and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210466832.7A CN114703169B (en) | 2022-04-29 | 2022-04-29 | L-threonine aldolase mutant R318L/H128N and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114703169A true CN114703169A (en) | 2022-07-05 |
CN114703169B CN114703169B (en) | 2023-10-31 |
Family
ID=82177016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210466832.7A Active CN114703169B (en) | 2022-04-29 | 2022-04-29 | L-threonine aldolase mutant R318L/H128N and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114703169B (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106748854A (en) * | 2016-12-01 | 2017-05-31 | 暨明医药科技(苏州)有限公司 | A kind of preparation method of Droxidopa |
CN110272856A (en) * | 2019-05-08 | 2019-09-24 | 江南大学 | A kind of recombinant bacterium that expressing D-Thr aldolase and its construction method and application |
CN110592058A (en) * | 2019-05-30 | 2019-12-20 | 重庆大学 | Threonine aldolase, coding gene thereof and application of threonine aldolase in droxidopa biosynthesis |
CN111394343A (en) * | 2020-04-22 | 2020-07-10 | 重庆大学 | L-threonine aldolase mutant R318L and application thereof |
CN111849951A (en) * | 2020-04-22 | 2020-10-30 | 重庆大学 | L-threonine aldolase mutant R318M and application thereof |
CN111849952A (en) * | 2020-04-22 | 2020-10-30 | 重庆大学 | L-threonine aldolase mutant R318V and application thereof |
CN112513010A (en) * | 2018-06-21 | 2021-03-16 | 意大利合成制造有限公司 | Enzymatic method for preparing droxidopa |
CN112941123A (en) * | 2021-02-25 | 2021-06-11 | 南京工业大学 | Method for biologically synthesizing droxidopa based on L-threonine aldolase |
CN113481188A (en) * | 2018-11-06 | 2021-10-08 | 王喆明 | Threonine aldolase mutant and application thereof in preparation of substituted phenylserine derivative |
-
2022
- 2022-04-29 CN CN202210466832.7A patent/CN114703169B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106748854A (en) * | 2016-12-01 | 2017-05-31 | 暨明医药科技(苏州)有限公司 | A kind of preparation method of Droxidopa |
CN112513010A (en) * | 2018-06-21 | 2021-03-16 | 意大利合成制造有限公司 | Enzymatic method for preparing droxidopa |
CN113481188A (en) * | 2018-11-06 | 2021-10-08 | 王喆明 | Threonine aldolase mutant and application thereof in preparation of substituted phenylserine derivative |
CN110272856A (en) * | 2019-05-08 | 2019-09-24 | 江南大学 | A kind of recombinant bacterium that expressing D-Thr aldolase and its construction method and application |
CN110592058A (en) * | 2019-05-30 | 2019-12-20 | 重庆大学 | Threonine aldolase, coding gene thereof and application of threonine aldolase in droxidopa biosynthesis |
CN111394343A (en) * | 2020-04-22 | 2020-07-10 | 重庆大学 | L-threonine aldolase mutant R318L and application thereof |
CN111849951A (en) * | 2020-04-22 | 2020-10-30 | 重庆大学 | L-threonine aldolase mutant R318M and application thereof |
CN111849952A (en) * | 2020-04-22 | 2020-10-30 | 重庆大学 | L-threonine aldolase mutant R318V and application thereof |
CN112941123A (en) * | 2021-02-25 | 2021-06-11 | 南京工业大学 | Method for biologically synthesizing droxidopa based on L-threonine aldolase |
Non-Patent Citations (4)
Title |
---|
RENFEN ZHA等: "Improving the Cβ stereoselectivity of L-threonine aldolase for the preparation of L-threo-3,4-dihydroxyphenylserine, a powerful anti-Parkinson\'s disease drug", 《BIOCHEMICAL ENGINEERING JOURNAL》 * |
赵文艳: "高立体选择性L-TA的基因挖掘、分子改造与应用研究", 《中国优秀硕士学位论文全文数据库》 * |
陈启佳等: "苏氨酸醛缩酶的催化机理、分子改造及合成应用", 《生物工程学报》, vol. 37, no. 12 * |
黎军等: "苏氨酸醛缩酶的研究进展", 《生物技术通讯》, vol. 30, no. 3 * |
Also Published As
Publication number | Publication date |
---|---|
CN114703169B (en) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111394343B (en) | L-threonine aldolase mutant R318L and application thereof | |
CN111849951B (en) | L-threonine aldolase mutant R318M and application thereof | |
CN111849952B (en) | L-threonine aldolase mutant R318V and application thereof | |
US11535839B2 (en) | Encoding genes of nitrilase mutants and application thereof | |
CN110592058B (en) | Threonine aldolase, coding gene thereof and application of threonine aldolase in droxidopa biosynthesis | |
JP4493333B2 (en) | Enzyme modification method and oxidoreductase mutant | |
CN109837317B (en) | Synthesis method of chiral bisaryl alcohol compound | |
CN107858340B (en) | High-catalytic-activity D-fructose-6-phosphate aldolase A mutant, recombinant expression vector, genetically engineered bacterium and application thereof | |
CN113846069B (en) | Amphetamine dehydrogenase mutant and application thereof in chiral amine synthesis | |
CN109321549B (en) | Directional modification enzyme of heparinase I with improved specific enzyme activity, molecular modification method and expression engineering bacteria | |
CN113025542B (en) | Recombinant escherichia coli for producing L-glutamine and construction method and application thereof | |
JP6853549B2 (en) | Modified meso-diaminopimelic acid dehydrogenase | |
Ørum et al. | Expression in E. coli of the gene encoding phenylalanine ammonia-lyase from Rhodosporidium toruloides | |
CN109384852A (en) | Recombinate preparation, characterization and the application of Martentoxin | |
CN114703169B (en) | L-threonine aldolase mutant R318L/H128N and application thereof | |
CN116287050A (en) | Imine reductase, mutant and application thereof in synthesis of tetrahydro-beta-carboline derivatives | |
CN112280760B (en) | Glutamic dehydrogenase mutant and application thereof | |
CN112941123A (en) | Method for biologically synthesizing droxidopa based on L-threonine aldolase | |
CN112961873A (en) | Method for synthesizing norepinephrine by double-enzyme coupling | |
CN108690837B (en) | Method for improving heat stability of polymer protein and alcohol dehydrogenase with improved heat stability | |
CN112322607B (en) | Fusion type nitrile hydratase and application thereof | |
CN115011569B (en) | Bose NemR-PS mutant and application thereof in preparation of (S) -citronellol | |
KR20020056894A (en) | Novel carbonyl reductase, gene thereof and method of using the same | |
KR102075740B1 (en) | A Novel Soluble Methane Monooxygenase Identified By High-Throughput Enzyme Screening System | |
CN108624571B (en) | Enzyme with function of catalyzing DHAP or D-G3P to synthesize acrylic acid and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |